Aeterna Zentaris Inc (NASDAQ:AEZS)
| 2.63 Delayed Data As of Mar 27 |  0.00 / 0.00%Today’s Change | 2.54 Today|||52-Week Range 9.75 | -17.30% Year-to-Date |
Latest AEZS News | Press Releases
| Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates Mar 23 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.63 |
| Today’s open | 2.63 |
| Day’s range | 2.63 - 2.63 |
| Volume | 100 |
| Average volume (3 months) | 15,217 |
| Market cap | $12.8M |
Data as of 10:18am ET, 03/27/2023
Growth & Valuation
| Earnings growth (last year) | -157.13% |
| Earnings growth (this year) | +29.49% |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | +7.22% |
| P/E ratio | NM |
| Price/Sales | 2.73 |
| Price/Book | 0.36 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CLXTCalyxt Inc | +0.00 | +0.91% |
| HTGMHTG Molecular Diagno... | +0.14 | +3.94% |
| OPGNOpGen Inc | +0.02 | +1.40% |
| SASISigma Additive Solut... | -0.01 | -2.31% |
Data as of 3:59pm ET, 03/28/2023
Financials
| Next reporting date | May 10, 2023 |
| EPS forecast (this quarter) | -$0.93 |
| Annual revenue (last year) | $5.6M |
| Annual profit (last year) | -$22.7M |
| Net profit margin | -402.96% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Toronto, Ontario |
Forecasts
